Healthtech_Leaders_horizontal


Healthtech Leaders Agenda

Tuesday 10 May 2022
(All times in GMT)


Welcome Address

Becky Johnson, Conference Director, LSX

Becky Johnson, Conference Director, LSX


The Evolution Of Healthcare & The Role Of Digital In The Transition To A Value Based Approach

With pressure on global health systems, providers and staff increased to unsustainable levels, the COVID-19 pandemic has highlighted the need for radical change in healthcare, but also how much can be achieved in a time of crisis. Looking forward, a totally different approach to care organization, delivery and distribution will be needed to help deliver better outcomes, improved patient and staff experience and lower cost of care. This keynote session explores the need more than ever to step up collaboration, information and knowledge sharing, and agility in the delivery of diagnostic and monitoring systems at scale. How we can utilise the technology that can collect, qualify, and analyze data in ways that quickly reveal patterns and hidden insights and examine the ways in which the pandemic has spurred the move to virtual care and how remote patient management can provide valuable relief to healthcare systems.

Jan Kimpen, Chief Medical Officer, Philips

Jan Kimpen, Global Chief Medical Officer, Philips


The Fight For Healthtech Investment Opportunities Post Pandemic – Are The Tables Turning For Investors?

Evolution in the healthcare market and the way care is delivered has changed dramatically over the past 12 months, with the way the entire populations have been receiving healthcare flipping to a predominantly technology focused approach and the amount of money being invested within healthtech reaching new heights. This is leading to a lot of companies getting access to large amounts of money and can commercially scale faster, however where once companies had to fight to get investors over the line, investors are now fighting to compete for the best companies in a company driven market. A panel of experts discuss

  • What impact has Covid-19 had on healthtech and digital health investment?
  • How do digital health companies typically demonstrate value?
  • Which value pools are investors most excited about?
  • Traditional investors vs new investors in this space

Moderator: Rachel Ford Hutman, Founder and CEO, Ford Hutman Media
Steve Tolle, General Partner, HLM Venture Partners 
Assaf Barnea, CEO, Sanara Ventures
Michael Niddam, Co-Founder & Managing Director, Kamet Ventures 
Rana Lonnen, Managing Director, dRx Capital, Novartis 
Christoph Kausch, Managing Partner, MTIP

Rachel Ford Hutman, Founder and CEO Hutman Media 300x    Steve Tolle, Partner, HLM Ventures-1    Assaf Barnea, CEO, Sanara Ventures    Michael Niddam, Co-Founder, Kamet Ventures 300x    Rana Lonnen, Head of Search and Evaluation, Strategic Capital, Novartis    Christoph Kausch, Managing Partner, MTIP


Morning Break


Pharma’s Transformation Through Digital Innovation – The Merging Of Healthcare & Technology As A ‘Full Stack’ Opportunity

It is no secret that digital transformation in the pharmaceutical industry is crucial for improved patient care, cost-effectiveness, greater transparency, improved production and drug development. Add to that the acceleration of adoption of various digital technologies in order to overcome the challenges caused by the pandemic and there has never been a more pivotal time within pharma and healthcare. A panel of pharma leaders discuss the changes they are implementing and what the vision for ‘after’ Covid entails

  • How has the pandemic changed the perception of digital and shifted towards a more innovatively focused approach?
  • Cross industry collaboration and what this looks like in reality
  • Digital as a tool to create better experiences for patients and physicians
  • Acceleration of clinical development through multiple investable and scalable solutions
  • The importance of data modelling, platforms and science in the development of healthcare solutions and services

Moderator: Hanno Ronte, Partner, Monitor Deloitte
Nazar Rasul, Global Head of Digital, Fresenius Kabi
Gregoire Guillet, Chief Business & Value Officer – WeHealth Digital Medicine, Servier
Richard Cassidy, VP Rx+Global, Astellas Pharma

Hanno Ronte, Partner, Monitor Deloitte    Nazar Rasul, VP Global Head of Digital, Fresenius Kabi   Gregoire Guillet, Chief Business & Value Officer – WeHealth Digital Medicine, Servier    Richard Cassidy, VP Rx+Global, Astellas Pharma


Measuring Digital Transformation Progress & Assessing The Key Opportunities Ahead

The life sciences industry is at an inflection point. While life sciences companies understand that the digitally enabled organization is the future of health, many approached digital transformation pre–COVID-19 in a more targeted and incremental way that lacked a holistic business transformation lens. In an increasingly digital, patient-experience, and insight-driven health care world, an uncoordinated approach to digital transformation simply won’t work any longer. Hear insights on how life sciences executives are making focused digital technology investments that are coming together to change the status quo and transform activities across functional areas and value streams. Hear how such leapfrog digital innovation could bring transformative benefits, including realizing ambitious goals earlier, engaging patients and partners optimally, and bringing drugs to market faster.

Hanno Ronte, Partner, Monitor Deloitte

Hanno Ronte, Partner, Monitor Deloitte


Big Tech, Big Ideas: How Are The World’s Biggest Tech Companies Addressing Healthtech’s Biggest Challenges

A panel of big tech players, both established, new entrants and those looking to scale back their offering within the healthcare space, debate and discuss their respective strategies regarding the industry, focussing on enabling patients, improving clinical, operational effectiveness and personalised care and what’s next for healthcare?

  • What are the differing strategies of tech giants and where do they see their roles in the fast-moving world of digital healthcare?
  • Mega-alliances and collaborative ecosystems; how are tech leaders building the future of healthcare?
  • In what ways are big tech leveraging and adapting their core business strengths for healthcare application

Moderator: Rachel Ford Hutman, Founder and CEO, Ford Hutman Media
Mark Davies, Chief Medical Officer, IBM
Susan Thomas, Clinical Director, Google Health UK
Neil Jordan, Worldwide General Manager, Retail Health Innovation, Microsoft 

Rachel Ford Hutman, Founder and CEO Hutman Media 300x    Mark Davies, Chief Medical Officer, IBM    Susan Thomas, Clinical Director, Google Health UK    Neil Jordan, WW General Manager Retail Health Innovation, Microsoft


Lunch Break


In The Digital Therapeutics Race What Is The Best Route To Success?

Digital therapeutics have been gaining traction for years, but the digital health field’s explosive growth during Covid-19 pandemic is helping these companies carve out a space in the market for their products. Federal regulators loosened some requirements to make digital health tools more accessible and DTx companies saw an opportunity to prove their worth, however the sector still face challenges that could slow its widespread adoption. A panel of DTx advocates discuss the challenges this growing sector face and how they are overcoming them

  • Clinician and patient engagement and trust regarding digital health tools in healthcare
  • Real world data and evidence to evaluate and measure value
  • Route to market and categorising DTx within healthcare ecosystems
  • Perspectives on pharma-DTx partnerships

Moderator: Megan Coder, Vice President of Global Policy, Digital Therapeutics Alliance
Caoimhe Vallely-Gilroy, Global Head of Digital Health & Therapeutics, Merck 
Chris Robson, CEO, Living With 
Zach Henderson, Chief Commercial Officer, Glooko
Robert Garber, Partner, 7WireVentures

Megan Coder, Vice President of Global Policy, Digital Therapeutics Alliance   Caoimhe Vallely-Gilroy, Global Head of Digital Health & Therapeutics, Merck    Chris Robson, CEO, Living With    Zach Henderson, Chief Commercial Officer, Glooko    Robert Garber, Partner, 7Wire Ventures


Key Success Factors In Healthtech Fundraising

A panel of healthtech companies discuss the key success factors for raising early-stage capital, identifying the key pitfalls of the current fundraising environment and debating how, in an increasingly competitive sector, healthtechs with potentially unproven products can distinguish their product and demonstrate concrete outcomes.

  • Demonstrating USPs and proving use cases - differentiating yourselves from competition
  • Gaining traction with investors - how much and what data and business models do investors need to see?
  • Ensuring protection of your innovation and proving commercial strategy

Moderator: Tony Proctor, Partner, Potter Clarkson
Alexander Chekan, Chief of Staff, Palta

Tony Proctor, Partner, Potter Clarkson    Alexander Chekan, Chief of Staff, Palta


Afternoon Break


The Rise And Growth In The Market, What Is Next For Women’s Healthtech - A 360 Degree Perspective Of Investment, Partnering & Deal Making

The global women’s healthtech market is already valued at $1.5 billion in 2020 and is expected to have a CAGR of 20% this decade. With investment pouring into the market and a spotlight shone from healthcare commercial leaders looking for deals and partnerships, it’s an exciting time for an underserved industry. What are the drivers behind the rise of the industry and what shape will this growth take? A multi-stakeholder panel from across the women’s health technology industry discuss the drivers in the market, their vision for the future convergence in combining technologies, and most importantly – what’s next?

Moderator: Annemijn Eschauzier, Mentor; former CMO Women's Health, GE
Berthold Hinzen, Head of Licensing Women’s Health, Radiology & New Spaces, Bayer 
Jessica McCreadie, Principal, Octopus Ventures
Keren Leshem, CEO, Ocon Healthcare 
Lea Von Bidder, Co-Founder and President, Ava Health

Annemijn Eschauzier, CMO, Previously GE Healthcare    Berthold Hinzen, Head of BD&L Therapeutic Areas, Bayer    Jessica McCreadie, Principal, Octopus Ventures    Keren Leshem, CEO, OCON Healthcare    Lea Von Bidder, Co-Founder and President, Ava Health


How Genomics Is Revolutionising Healthcare & What Does The Future Hold?

By 2025 the size of the global genomics market is predicted to reach £24B, with next generation sequencing revolutionising the industry and genomics technology having changed dramatically over the last few years - the possibilities created by improved knowledge of the human genome are almost limitless. The genomics industry is hugely diverse, ranging from companies using genomic data to identify new drug targets to those developing technologies for sequencing genomes more quickly, cheaply and accurately than ever before. A panel of genomic innovators and stakeholders explain the ever-increasing potential of genomics in healthcare and life sciences, and the challenges which the ecosystem must still overcome in order to capitalise on this growing market.

Emma Stanton, VP Clinical, Oxford Nanopore Technologies
David Atkins, CEO, Congenica
Kari Stefansson, CEO, deCODE Genetics 
Parker Moss, Chief Commercial Officer, Genomics England

Emma Stanton VP Clinical, Oxford Nanopore Technologies    David Atkins, CEO, Congenica    Kari Stefansson, CEO, deCODE Genetics    Parker Moss, Chief Commercial Officer, Genomics England


Networking Party


Wednesday 11 May 2022
(All times in GMT)


Welcome Address

Becky Johnson, Conference Director, LSX

Becky Johnson, Conference Director, LSX


The Year That Changed The World Forever – Looking Forward Through A Post Pandemic Lens

Rajeev Ronanki, President, Digital Platforms, Anthem

Rajeev Ronanki, President, Digital Platforms, Anthem


Advancing The Role Of Real-World Data To Support The Development Of The Healthtech Landscape & The Future Of Medicine

The digitalisation of medical records has created access to reams of data about patient outcomes, but with so much information, not all of it has found a use. Real world evidence in and of itself is just that, data; it is the insights garnered and the questions answered because of it that really make this data invaluable. A panel of experts discuss the increasingly important role that real world data is playing within healthtech and what possibilities the future holds for this vital resource.

  • How important is it to increase and improve communication on the benefits of generation and use of RWD?
  • How is the industry most innovatively leveraging RWD for clinical and observational research?
  • How can use of RWD most effectively drive effective outcomes?

Moderator: Bleddyn Rees, Chair, The Digital Health Society; Board Director, ECHAlliance
Ali Hasan, Chief Medical & Healthcare Officer, Vitality Health
Dan Vahdat, CEO, Huma
Arif Nathoo, CEO, Komodo Health
Jill Waldner, Vice President, Evidation Health
Madelyn Herzfeld, Founder & Vice Chairman, Carevive

Bleddyn Rees, Chair, The Digital Health Society; Board Director, ECHAlliance   Ali Hasan, Chief Medical & Healthcare Officer, Vitality Health    Dan Vahdat    Arif Nathoo, CEO, Komodo Health    Jill Waldner, Vice President, Evidation Health    Madelyn Herzfeld, Founder & Vice Chairman, Carevive


Morning Break


Digital Healthtech Business-Building & The Emergence Of Digital Health Ecosystems

  • Building, scaling and business building strategies for digital health tech companies
  • Introduction of digital health ecosystems and case studies of emerging digital health ecosystems
  • Opportunities for healthcare companies around partnering with digital health ecosystems

Tobias Silberzahn, Partner, McKinsey

Tobias Silberzahn, Partner, McKinsey


Creating Meaningful Partnerships In Pharma: A Deep Dive Into What Healthcare’s Commercial Leaders Are Looking For When It Comes To Innovation, Acqusitions & Partnerships

As health systems find themselves increasingly under pressure, pharma has a unique opportunity to broaden the basis of their engagement with healthcare systems and can look to build trusted partnerships around a common purpose of supporting the delivery of better patient outcomes, data driven insights to improve treatment and care pathways to optimise the use of healthcare resources. A panel of commercial leaders at the forefront of this drive for innovation discuss their aims and vision for the year ahead

  • Re-defining the relationship between pharma and healthcare systems
  • Requirements for successful trusted partnerships
  • Partnership models: From transactional to relationship building
  • The rise of DTx & Pharma

Gregg Talbert, SVP Head of Personalised Healthcare and Digital Partnering, Roche 
Mats Berggren, Head of Search & Evaluation, Digital Innovation and External R&D, Merck 
Anne-Kathrin Witt, Global Head Digital BD&L, Novartis
Ethan Wergelis-Isaacson, Digital Health Strategy, Otsuka 

Gregg Talbert, SVP Head of Personalised Healthcare and Digital Partnering, Roche    Mats Berggren, Director, Digital Business Innovation & External Collaboration Models, M-Digital Lead, Merck KGaA    Anne-Kathrin Witt, Director Digital BD&L, Novartis    Ethan Wergelis-Isaacson, Digital Health Strategy, Otsuka


The Digitalisation Of Hospitalisation – How The Hospitals Of Today Are Looking To The Technology Of Tomorrow, To Provide A Patient First Vision Of Healthcare From Admission To Discharge

Digitalisation is causing upheaval across society and throughout the globe, from videoconferencing disrupting traditional ways of working to the boom of ecommerce overtaking high street shops. This digital disruption has gone right to the heart of healthcare and hospitals as well, with health systems having to now focus on meeting the expectations of increasingly sophisticated consumers. The impact of this disruption will last beyond the pandemic and digitalising healthcare institutions will be a mammoth task – but the past 18 months have shaken this sector causing them to regroup, adapt and plot a path to the future. A group of experts discuss their vision for the hospitals of the future and the road they are taking to get there

  • Coordination and interoperability as a barrier to digital transformation, driving efficiencies and streamlining patient care
  • Cyber security: Building a robust digital foundation to guard against data loss and adoption of connected devices
  • Innovation and intelligent automation: Bringing efficiency benefits, intelligent automation of business processes and core clinical processes

Eyal Zimlichman, Chief Medical Officer & Chief Innovation Officer, Sheba Medical Center
Adam Landman, Chief Information and Digital Innovation Officer, Brigham Women’s Hospital
David Norton, Senior Lead Innovation Consultant, Royal Free London Foundation Trust
Neil Gomes, System SVP for Digital & Human Experiences, Common Spirit Health 
Sarah Yusuf, Consultant Radiologists & Group Director, Sandwell and West Birmingham NHS Trust

Eyal Zimlichman, Chief Innovation and Medical Officer, Sheba Medical Centre    Adam Landman, Chief Information and Digital Officer, Brigham and Women’s Hospital 300x    David Norton, Senior Lead Innovation Consultant, Royal Free London Foundation Trust    Neil Gomes, System SVP, Digital Human Experiences, Common Spirit Health    Sarah Yusuf, Consultant Radiologists & Group Director, Sandwell and West Birmingham NHS Trust


Lunch Break


The Powerhouse Of Digital Transformation – How We Can Prevent The Next Epidemic Or Pandemic Through Ai & Convergence

As we’ve seen with COVID-19, viruses can be major slayers to public health and the world’s economy. There's real concern about what the next big virus might be, the mutations of COVID-19 into seasonal diseases, and/or viruses teaming up to take down people. Thankfully, there is hope! Taking a page from manufacturing, we can combine artificial intelligence (AI) and generative design to identify millions of potential virus outbreaks. Armed with this knowledge (and virus genomics), researchers could pinpoint preventive measures, or perhaps even a vaccine before the viral outbreak...and allow us to stop an epidemic, let alone a pandemic, before it even occurs.

Neil Sahota, Artificial Intelligence Advisor, United Nations; Interim CEO ACSILabs 

Neil Sahota, United Nations Artificial Intelligence Advisor & Interim CEO, ACSILabs


How AI, Machine Learning & Big Data Are Disrupting The Drug Discovery & Development Landscape For Faster And More Accurate Lead Identification

Drug discovery is ripe for disruption. A time consuming and expensive process, taking years and costing billions, the industry is crying out for faster and more accurate drug targets to test at clinical trials. However technology has not been able to keep up, until now. A panel of leaders discuss the future possibilities and applications

  • The role in cost cutting of new drug spend and development times
  • AI collaboration to target, identify and diagnose faster
  • Gaining insights from clinical trial data

Daniel Neil, SVP AI, Benevolent AI
Martin-Immanuel Bittner, CEO, Arctoris
Neil Sahota, Artificial Intelligence Advisor, United Nations; Interim CEO ACSILabs 
Djork-Arne Clevert, Director Machine Learning, Bayer

Daniel Neil, SVP AI, Benevolent    Martin-Immanuel Bittner, CEO, Arctoris    Neil Sahota, United Nations Artificial Intelligence Advisor & Interim CEO, ACSILabs    Djork-Arne Clevert, Director Machine Learning, Bayer


A Spotlight On The Brightest Next Generation Of Healthtech Startups

Amidst the pandemic crisis, the healthcare and life science industries have come under increased scrutiny, be it global, national or private healthcare providers. However, healthtech has never been so top-of-mind as companies scaled up to meet pandemic demand. 2020 saw record highs of investment within European healthtech, jumping up by $750m from the previous year and some hefty funding rounds with many telemedicine and digital diagnostic startups seeing huge jumps in user numbers. With the focus firmly on healthtech for the foreseeable future and the global healthtech industry currently worth a staggering $8tn, a panel of the latest and greatest startups discuss their ambition and vision for growth in this competitive landscape

Max Parmentier, Founder, Birdie
Cyndi Williams, CEO, Quin 
Paul Landau, CEO, Careology 
Caroline Noublanche, CEO, Apricity 

Max Parmentier, Chief Executive Officer & Co-Founder, Birdie    Cyndi Williams, CEO, Quin    Paul Landau, CEO, Careology    Caroline Noublanche, CEO, Apricity

DOWNLOAD BROCHURE